AlphAIAlphAI — Financial news for AI agents
investing.comSEP 211 min read$ALMR

Why is Alamar Biosciences stock surging today?

Alamar Biosciences (ALMR) stock rose 10.3% to $38.44 in pre-market trading after reporting Q2 2026 revenue growth of 82% YoY to $29.4M and raising full-year revenue guidance to $116M-$120M. Analysts increased price targets, and the company expanded a partnership with the Alzheimer’s Disease Data Initiative.

Original reporting
investing.com
Published Sep 21, 2026, 9:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ALMR
Bullish
high confidence
Mentioned
$ALMR
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALMRBullishLow
01

Why it matters

The recap reinforces the bullish sentiment but offers no new actionable catalyst.

02

Market read

The article is a recap of already‑public earnings; relevance for traders is limited.

03

What to watch

Potential upcoming regulatory or clinical trial updates could change outlook.

Relevance 4/10Novelty 2/10Timing: pre‑market today

Background

Alamar Biosciences reported Q2 2026 results with 82% revenue growth and raised FY guidance, prompting a 10% pre‑market rally.

Company-level read

Ticker impact

$ALMRBullishHigh confidence
Context

Alamar Biosciences stock jumped 10.3% pre‑market after Q2 2026 results and raised guidance were recapped.

Expected impact

Limited upside; move likely exhausted.

Evidence & confidence

The article repeats prior earnings data; traders have already priced the news.

Market effects

Sector

None beyond Alamar; peers mentioned without new news.

Regional

U.S. market risk‑on backdrop modestly supportive.

Global

Low; story is company‑specific.

Counterpoint

What could challenge this read

The rally may be overdone given the lack of fresh information.

Key entities

  • company
    Alamar Biosciences

    Life‑science tools firm (ticker ALMR).

Read at source← All news

Related articles

AUG 18
$ALMRMedAI 8/10

Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.

fool.com7 min
AUG 11
$ALABHighAI 9/10

Alamar Biosciences Shares Rise 18% After Second-Quarter Revenue Jumps 82% Year-Over-Year

Alamar Biosciences shares rose about 18% after the company reported Q2 2026 revenue of $29.4 million, up 82% year over year, and provided first full-year 2026 revenue guidance of $116 million to $120 million. The stock closed at $32.91. Alamar also launched new NULISAseq panels and set targets to exceed 100 instrument systems and $400,000+ annual pull-through per instrument.

ibtimes.com.au6 min
AUG 10
$ALMRHigh

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance FREMONT, Calif.--August 10, 2026 (GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detectio

SEC EDGAR 8-K4 min
JUL 15
$ALMRMed

Alamar Hits A High Note On Alzheimer's Buzz

Alamar Biosciences (ALMR) shares rose 7.3% to a 52-week high of $28.42 after the company said its NULISA platform will be featured in more than 140 presentations at the Alzheimer’s Association International Conference, according to the company. The article notes no earnings or analyst action and contrasts weaker moves at peers like TMO and ILMN.

yahoo.com4 min